> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Cipla Gets 1-item 483 After May Inspection
- URL: https://www.fdaweb.com/cipla-gets-1-item-483-after-may-inspection/
- Published: 2024-06-07T12:00:00.000Z
- Updated: 2026-09-14T14:32:45.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157140

An inspection last month at Cipla Ltd.’s Maharasthra, India active pharmaceutical ingredient and finished dosage manufacturing facility resulted in a one-item [Form FDA-483](https://www.fda.gov/media/179231/download?attachment&ref=fdaweb.com) that cited its quality system.

FDA investigators said the firm’s responsibilities and procedures for the quality control unit are not fully followed -- personnel failed to follow document control procedures during a walk-through of the stability chambers located in the facility’s warehouse unit.